Friday, 17 Aug 2018

You are here

The RheumNow Week in Review – 6 May 2016

Highlights from this week on include:

  1. Registry study (ARTIS & DANBIO) of Spondyloarthritis & Psoriatic arthritis patients show NO cancer risk associated with SpA or PsA; moreover TNF inhibitor use does not augment the cancer risk in these patients. 
  2. May is lupus awareness month. 
  3. CARDERA-2 clinical trial of 154 early RA pts showed that Anakinra+MTX was not better than MTX alone- in early RA - both Xray & clinical outcomes. Questions the value of anakinra in RA.  
  4. Health Canada approves secukinumab for use in psoriatic arthritis and anklylosing spondylitis 
  5. Acute scrotal swelling in Henoch Schonlein purpura occurs in 10-30% of boys, 60% are unilateral.  Treatment with steroids? 
  6. Late onset SLE (>50yrs) patients have less cutaneous disease (malar rash, photosensitivity, livedo) but more Sicca Sx 
  7. Metanalysis: TNF inhibitors are shown to be associated with an increase risk of perioperative infections (SSI): BUT the infection risk decreases >38% with temporary cessation of TNFi before surgery. 
  8. Dr. Nicola Dalbeths #Gout review in Lancet is stellar! She's leading the field w/ DECT scans, research & smart Rx. 
  9. RheumNow posts a free download – Patient Guide to Biologics  
  10. FDA REMS/Safety Panel Backs Educational Requirements for Opioid Prescribers 
  11. Simple Referral Rule May Lead to Earlier Referral and Diagnosis of Axial Spondyloarthritis. Rule: needs to 2 of 4 to refer suspected SpA – 1) inflammatory low back pain; 2) back pain > 5 yrs.; 3) good response to NSAIDs; and 4) family history of spondyloarthritis. 
  12. CDC Updates Arthritis Numbers – 25% of US adults have arthritis. 
  13. Poor Outcomes for Dermato/Polymyositis Admitted to ICU. 
  14. Can Rituximab Change the Course of Interstitial Lung Disease.  
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

ACR Meets With HHS Secretary Azar to Discuss Step Therapy Concerns

Yesterday, the American College of Rheumatology (ACR) met with U.S. Department of Health and Human Services Secretary Alex Azar for a productive discussion about the rheumatology community's concerns with a new policy that will allow Medicare Advantage plans to utilize step therapy in Medicare Part B. In the meeting, the ACR expressed concerns that this policy would delay rheumatology patients' access to treatments.

The RheumNow Week in Review – We’re Number One! (8.17.18)

Dr. Cush reviews the articles and news from the last week on Information on comorbidities, the downside of steroids, unmet need in psoriatic arthritis, and the top 10 rheumatology programs.

U.S. News 2018-19 Rheumatology Rankings

The Annual U.S. News and World Report Rankings of Hospitals has listed the top contenders in the field of rheumatology. The U.S. News Review rates hospitals nationwide in 16 specialties – including rheumatology. Of the 4,500 hospitals covered by U.S. News that were analyzed, 158 were classified nationally in at least one specialty area.

The RheumNow Week in Review – No Good Gout (8.10.18)

Dr. Jack Cush reviews the news and latest journal articles from the past week on Info on Surgery and Hip Fractures, Gout drugs abandoned, Allopurinol escalation, hydroxychloroquine drug levels, how to treat scleroderma in India and exactly who gets back pain.

The RheumNow Week in Review – Handshakes or Hugs (8.3.18)

Dr. Jack Cush reviews the news and highlights from the past week on, including new treatments for LTBI, gout consequences, RA and offspring risk, PsA risk, and the opioid epidemic effects.